<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104776</url>
  </required_header>
  <id_info>
    <org_study_id>0209-01</org_study_id>
    <nct_id>NCT04104776</nct_id>
  </id_info>
  <brief_title>A Study of CPI-0209 in Patients With Advanced Tumors</brief_title>
  <official_title>A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in&#xD;
      patients with advanced tumors alone and in combination with other therapies. CPI-0209 is a&#xD;
      small molecule inhibitor of EZH2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Frequency of Dose-limiting toxicities (DLTs)</measure>
    <time_frame>DLTs assessed during Cycle 1 (first 28 days on study for monotherapy and first 21 days for combination therapy)</time_frame>
    <description>The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CPI-0209 as monotherapy and in combination with irinotecan in patients with advanced tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and change in laboratory values</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve versus time (AUC)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Lymphoma, T-Cell</condition>
  <condition>Mesothelioma, Malignant</condition>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Phase 2: Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-0209 will be dosed once per day orally in 28 day cycles.&#xD;
Cohort M1: Open to patients with urothelial carcinoma (with known ARID1A mutation)&#xD;
Cohort M2: Open to patients with ovarian clear cell carcinoma (with known ARID1A mutation)&#xD;
Cohort M3: Open to patients with endometrial carcinoma (with known ARID1A mutation)&#xD;
Cohort M4: Open to patients with lymphoma (of either B-cell or T-cell histology), including germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) patients with EZH2 mutation&#xD;
Cohort M5: Open to patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss&#xD;
Cohort M6: Open to patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-0209 will be dosed once per day orally in 21 day cycles. Irinotecan iv will be dosed once every 3 weeks (Q3W).&#xD;
• Cohort C1: Open to patients with small cell lung cancer (SCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-0209</intervention_name>
    <description>CPI-0209 alone</description>
    <arm_group_label>Phase 2: Combination Therapy</arm_group_label>
    <arm_group_label>Phase 2: Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>CPI-0209 in combination with irinotecan</description>
    <arm_group_label>Phase 2: Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 2:&#xD;
&#xD;
          -  Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
        For Cohort M1, the following criteria should be considered:&#xD;
&#xD;
          -  Histologically confirmed locally advanced unresectable or metastatic urothelial&#xD;
             carcinoma with predominant urothelial histology&#xD;
&#xD;
          -  Known ARID1A mutation&#xD;
&#xD;
          -  Disease progression during or following prior chemotherapy&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
        For Cohort M2, the following criteria should be considered:&#xD;
&#xD;
          -  Histologically confirmed advanced ovarian clear cell carcinoma&#xD;
&#xD;
          -  Known ARID1A mutation&#xD;
&#xD;
          -  Received at least 1 line of platinum-based chemotherapy&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
          -  Patient must have disease progression after previously receiving effective and&#xD;
             available standard of care treatment for clear cell ovarian cancer per local clinical&#xD;
             practice&#xD;
&#xD;
        For Cohort M3, the following criteria should be considered:&#xD;
&#xD;
          -  Histologically or cytologically confirmed recurrent, metastatic, or unresectable&#xD;
             endometrial carcinoma&#xD;
&#xD;
          -  Known ARID1A mutation&#xD;
&#xD;
          -  Received at least 1 line of platinum-based regimen in recurrent/metastatic setting&#xD;
&#xD;
          -  Documented microsatellite instability (MSI)-high or deficient mismatch repair (dMMR)&#xD;
             tumors should have received, or not be considered eligible for therapy with an&#xD;
             anti-PD-1 agent&#xD;
&#xD;
          -  Brachytherapy is allowed if completed &gt;12 weeks before the first dose of study drug&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
          -  Patients must have previously received effective and available standard of care&#xD;
             treatment options for endometrial cancer per local clinical practice&#xD;
&#xD;
        For Cohort M4, the following criteria should be considered:&#xD;
&#xD;
          -  Histologically confirmed lymphoma, with relapsed or refractory disease following 2 or&#xD;
             more prior lines of standard therapy&#xD;
&#xD;
          -  Not considered candidates to receive CAR-T or autologous hematopoietic stem cell&#xD;
             transplant (ASCT) as assessed by the treating investigator&#xD;
&#xD;
          -  Patients must not have received ASCT or CAR-T treatment for ≥90 days since the start&#xD;
             of the procedure OR ≥8 weeks since most recent systemic anti-DLBCL therapy&#xD;
&#xD;
          -  At least 1 bi-dimensionally measurable lesion on imaging scan defined as &gt;1.5 cm in&#xD;
             its longest dimension&#xD;
&#xD;
        For Cohort M5, the following criteria should be considered:&#xD;
&#xD;
          -  Pleural or peritoneal relapsed/refractory mesothelioma&#xD;
&#xD;
          -  Must have progressed on or after at least 1 prior line of active therapy&#xD;
&#xD;
          -  Measurable disease per modified RECIST 1.1&#xD;
&#xD;
          -  Known BAP1 loss per immunohistochemistry (IHC) or NGS&#xD;
&#xD;
        For Cohort M6, the following criteria should be considered:&#xD;
&#xD;
          -  Have measurable soft-tissue disease&#xD;
&#xD;
          -  Documented metastatic disease&#xD;
&#xD;
          -  Disease progression while on prior therapies&#xD;
&#xD;
          -  Baseline testosterone ≤50 ng/dL (≤2.0 nM) and surgical or ongoing medical castration&#xD;
             must be maintained throughout the duration of the study&#xD;
&#xD;
        For Cohort C1, the following criteria should be considered:&#xD;
&#xD;
          -  Histologically or cytologically confirmed ES-SCLC that relapsed within 6 months after&#xD;
             first-line chemotherapy with platinum-etoposide for at least 2 cycles&#xD;
&#xD;
          -  Prior immunotherapy is required&#xD;
&#xD;
          -  No prior topoisomerase 1 inhibitor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous solid organ or allogenic hematopoietic cell transplant&#xD;
&#xD;
          -  Known brain metatstases&#xD;
&#xD;
          -  Prior EZH2 inhibitor&#xD;
&#xD;
          -  Prior systemic anticancer treatment within 4 weeks of study treatment&#xD;
&#xD;
          -  Prior radiation therapy within 4 weeks of study treatment&#xD;
&#xD;
          -  Prior chemoembolization within 4 weeks of study treatment&#xD;
&#xD;
          -  Concomitant medication(s) or food or beverage that are moderate or strong CYP3A&#xD;
             inducers or inhibitors within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Major surgery within 4 weeks&#xD;
&#xD;
          -  GI disorders affecting absorption&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Suspected pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  Known additional malignancy that is active and/or progressive requiring treatment&#xD;
&#xD;
          -  Known HIV or active hepatitis&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Women of child bearing potential and men with reproductive potential, if they are&#xD;
             unwilling to use adequate contraception while on study therapy and for 3 months&#xD;
             thereafter&#xD;
&#xD;
          -  Patients unwilling or unable to comply with this study protocol&#xD;
&#xD;
        For Cohort C1, the following criteria should be considered:&#xD;
&#xD;
          -  Gilbert's disease or known homozygosity for UGT1A1*28 allele&#xD;
&#xD;
          -  Prior irinotecan or topotecan therapy&#xD;
&#xD;
        For Cohort M6, the following criteria should be considered:&#xD;
&#xD;
          -  Bone-only disease without nodal disease and no evidence of visceral spread&#xD;
&#xD;
          -  Structurally unstable bone lesions concerning for impending fracture&#xD;
&#xD;
          -  Prior treatment with:&#xD;
&#xD;
               -  First generation AR antagonists within 4 weeks of study treatment&#xD;
&#xD;
               -  5α reductase inhibitors, ketoconazole, estrogens (including DES), or&#xD;
                  progesterones within 2 weeks of study treatment&#xD;
&#xD;
          -  No planned palliative procedures for alleviation of bone pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Gates</last_name>
      <phone>404-727-3547</phone>
      <email>kelsey.gates@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>R. Donald Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McGettigan</last_name>
      <phone>773-702-1280</phone>
      <email>amcgettigan@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy Kindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Marlene and Stewart Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Carder</last_name>
      <email>Margaret.Carder@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Yixing Jiang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catie Elsier</last_name>
      <phone>617-643-0425</phone>
      <email>celsier@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Illy Dixon</last_name>
      <phone>617-632-5617</phone>
      <email>Illya_Dixon@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Leena Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffanie Barnhizer</last_name>
      <phone>734-647-8901</phone>
      <email>barnhize@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Tycel Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon S Skibinski-Preston, MPH</last_name>
      <phone>616-954-5552</phone>
      <email>shannon.skibinski@startmidwest.com</email>
    </contact>
    <contact_backup>
      <last_name>Yvette Cole, RN</last_name>
      <phone>616-389-1652</phone>
      <email>yvette.cole@startmidwest.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nehal Lakhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>chelsea.mccabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-4208</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perla Arriola</last_name>
      <email>Perla.Arriola@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Sabari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Fuhrman</last_name>
      <phone>513-584-8162</phone>
      <email>fuhrmaba@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Shuchi Gulati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Lurati, RN</last_name>
      <phone>210-593-5290</phone>
      <email>Tiffany.Lurati@startsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Choi, RN</last_name>
      <phone>210-593-2547</phone>
      <email>carrie.choi@startsa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Drew Rasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
      <email>AM7BD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska,, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Fang Qiu</last_name>
      <phone>206-215-6430</phone>
      <email>Chun-fang.Qiu@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Charles Drescher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Garcia</last_name>
      <phone>0034-616884422</phone>
      <email>mgarcia.ibsal@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Alejandro Martin Garcia-Sancho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Porter</last_name>
      <email>sarah.porter@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Harriet Walter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, B-cell</keyword>
  <keyword>Lymphoma, T-cell</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Topoisomerase I Inhibitors</keyword>
  <keyword>Topoisomerase Inhibitors</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

